What's Happening?
Chiesi Group is investing over €400 million to transition its pressurized metered-dose inhalers (pMDIs) to a next-generation propellant with low global warming potential. This initiative aims to reduce the carbon emissions associated with inhalers, which
are significant contributors to healthcare's carbon footprint. The new propellant, HFA-152a, is expected to cut emissions by up to 90% while maintaining the efficacy and usability of current inhalers. This move is part of Chiesi's broader commitment to achieving Net Zero greenhouse gas emissions by 2035.
Why It's Important?
The healthcare sector accounts for over 4% of global greenhouse gas emissions, with inhalers being a notable source. Chiesi's transition to a more sustainable propellant addresses the environmental impact of respiratory treatments while ensuring continuity of care for patients. This development aligns with global efforts to reduce carbon emissions and supports the European Union's climate objectives. It highlights the potential for innovation to drive sustainability in healthcare without compromising patient care.
What's Next?
Chiesi plans to integrate Carbon Minimal pMDIs seamlessly into the healthcare system, ensuring that patients can continue their treatments without increasing carbon emissions. The company is also committed to working with the respiratory community and industry peers to promote sustainable practices. This collective action is essential for achieving meaningful change in healthcare's carbon footprint.
